公告显示，上海檀英持有君实生物股份5945.93万股，股份性质为A股，占公司总股本的5.7914%。 北京商报讯（记者 丁宁）12月18日晚间，君实生物（688180）发布公告称，公司股东上海檀英投资合 伙企业（有限合伙）（以下简称"上海檀英"）长期看好公司的发展，因基金期限与流动性资金安排原 因，计划通过大宗交易的方式减持其持有的公司股份数量不超过2053.38万股，减持比例不超过公司总 股本的2%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年12月18日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 证券代码：688180 证券简称：君实生物 公告编号：临 2025-075 上海君实生物医药科技股份有限公司 关于持股 5%以上股东减持股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何 ...

Group 1 - Zhongwei Company plans to acquire controlling stake in Hangzhou Zhonggui through share issuance, with stock suspension starting December 19, 2025, for up to 10 trading days [1] - Qibin Group's subsidiary plans to establish Shenzhen Qibin New Energy Technology Co., with a registered capital of 600 million yuan to enhance photovoltaic glass supply chain efficiency [2] - Boying Special Welding's HRSG equipment is primarily matched with heavy gas turbines, with a production cycle of about 6 months, responding to increased demand in the U.S. market [3] Group 2 - Hongda Electronics' associate Jiangsu Zhanxin's application for IPO on the ChiNext has been accepted, with Hongda holding 13.79% of shares prior to the offering [5] - Yinxing Energy plans to acquire 50% stake in Tianjing Shenzhou for 20.15275 million yuan, which will enhance its renewable energy capacity [6] - Nandu Power's controlling shareholder has terminated plans for a change in control, leading to stock resumption on December 19, 2025 [7] Group 3 - Xibu Mining's subsidiary has obtained a mining license for iron resources, supporting sustainable development in the iron resource sector [9] - Shandong Expressway plans to provision for a long-term equity investment impairment of approximately 690 million yuan related to Dongxing Securities [10] - Tianfeng Securities has signed a supplementary agreement to extend the term of a 4 billion yuan subordinated debt by one year, with an adjusted interest rate of 4% [11] Group 4 - Shandong Zhanggu has received an administrative regulatory decision from the Shandong Securities Regulatory Commission for various compliance issues [12] - Nanjing Pharmaceutical plans to invest 120 million yuan to establish a medical device investment company, focusing on acquiring a stake in Ningbo Jiangfeng [13] - Hailianxun has received approval from the CSRC for a share swap merger with Hangzhou Steam Turbine, proceeding with related transactions [14] Group 5 - Luyuan Pharmaceutical reports normal operations with no significant changes in the internal and external business environment [15] - Nanhua Futures has set the H-share public offering price at 12 HKD per share, with expected listing on December 22, 2025 [17] - Visionox plans to invest 3.918 billion yuan in the second phase of the Hefei Guoxian AMOLED production line project, increasing its stake to 37.73% [18] Group 6 - Sichuan Road and Bridge has been acquired by Zhong Postal Insurance, reaching a 5% stake [19] - Boshuo Technology's directors plan to reduce their holdings by up to 18,300 shares [20] - O-film's controlling shareholder transferred 67.7048 million shares to settle debts, maintaining control with a 5.78% stake post-transfer [21] Group 7 - Junshi Biosciences' shareholder plans to reduce holdings by up to 2% through block trading [22] - Lihu Co. plans to reduce holdings by up to 2.98% through various trading methods [23] - Ruichen Environmental plans to reduce holdings by up to 3% through trading [25] Group 8 - Zhongfutong received a winning bid notification for a project worth approximately 411 million yuan [29] - Shikong Technology won a 141 million yuan project for smart cultural tourism integration [30] - Ningbo Construction's subsidiary won a 747 million yuan engineering project [31]

智通财经APP讯，君实生物(688180.SH)发布公告，上海檀英长期看好公司的发展，因基金期限与流动 性资金安排原因，计划通过大宗交易的方式减持其持有的公司股份数量不超过2053.38万股，减持比例 不超过公司总股本的2%。 ...

大股东持股的基本情况 截至本公告披露日，上海檀英投资合伙企业（有限合伙）（以下简称"上海 檀英"）持有上海君实生物医药科技股份有限公司（以下简称"公司"或"君实 生物"）股份 59,459,326 股，股份性质为 A 股，占公司总股本的 5.7914%。上述 股份为公司首次公开发行股票并在上海证券交易所科创板上市（以下简称"IPO"） 前取得的股份，且已于 2021 年 7 月 15 日起解除限售并上市流通。 证券代码：688180 证券简称：君实生物 公告编号：临 2025-075 上海君实生物医药科技股份有限公司 关于持股 5%以上股东减持股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 2 股东名称 上海檀英 股东身份 控股股东、实控人及一致行动人 □是 √否 直接持股 5%以上股东 √是 □否 董事、监事和高级管理人员 □是 √否 其他：不适用 持股数量 59,459,326股 持股比例 5.7914% 当前持股股份来源 IPO 前取得：59,459,326股 上述减持主体 ...

格隆汇12月18日丨君实生物(688180.SH)公布，公司于近日收到上海檀英出具的《关于君实生物减持计 划告知函》，上海檀英长期看好公司的发展，因基金期限与流动性资金安排原因，计划通过大宗交易的 方式减持其持有的公司股份数量不超过2053.38万股，减持比例不超过公司总股本的2%。上海檀英为在 中国证券投资基金业协会备案的私募基金，已成功申请适用《上市公司创业投资基金股东减持股份的特 别规定》和《上海证券交易所上市公司创业投资基金股东减持股份实施细则》的减持政策：拟通过大宗 交易方式减持的，在任意连续60日内减持股份的总数不超过公司总股本的2%，自本公告披露之日起15 个交易日后的三个月内进行。 ...

君实生物公告称，截至公告披露日，持股5.7914%的股东上海檀英，因基金期限与流动性资金安排，计 划在2026年1月13日至4月10日，通过大宗交易方式减持不超20,533,797股，即不超公司总股本2%。上海 檀英及一致行动人合计持股7.3263%，其在过去12个月内已减持公司1.1688%股份。本次减持计划存在 不确定性，但不会导致公司控制权变更，也不会对公司经营产生重大影响。 ...

证券日报网讯12月16日，乐普医疗（300003）在互动平台回答投资者提问时表示，截至目前，本公司及 关联方并未持有任何君实生物。 ...

Group 1 - The core viewpoint of the news is that Junshi Biosciences experienced a decline in stock price and significant trading activity, indicating potential investor concerns and market volatility [1] - On December 16, Junshi Biosciences' stock fell by 2.19%, with a trading volume of 197 million yuan, and a net financing outflow of 1.68 million yuan [1] - The total margin balance for Junshi Biosciences reached 1.377 billion yuan, with the financing balance accounting for 4.97% of the circulating market value, indicating a high level of leverage compared to the past year [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2] - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, representing a year-on-year growth of 42.06%, while the net profit attributable to shareholders was -596 million yuan, an increase of 35.72% year-on-year [2] - As of September 30, 2025, the number of shareholders increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2]

Group 1 - The establishment of the "China International Science and Technology Promotion Association Mother Fund Branch" aims to enhance the role of mother funds in China's capital market, promoting the flow of social capital to innovative and entrepreneurial enterprises [1][44] - The Fujian Province Minrong Bank AIC Fund was launched with a target scale of 2 billion yuan, focusing on sectors such as information technology, artificial intelligence, and healthcare [3][6] - The Jiangsu Yancheng Green Low-Carbon Industry Special Mother Fund has registered its first industrial sub-fund with a total scale of 500 million yuan, targeting investments in new energy and green technologies [7][8] Group 2 - The Guangming Science and Technology Innovation Mother Fund has officially started operations with a target scale of 5 billion yuan, focusing on seed and angel investments in the "2 0+8" industrial clusters in Shenzhen [29][31] - Hunan Caixin Capital has completed investments in two intelligent enterprises, demonstrating its capability to integrate resources and support technological innovation [33] - The Anhui Gaotou Guotai Haitong Health M&A Fund has successfully registered with a scale of 500 million yuan, focusing on innovative drug development in the biopharmaceutical sector [34] Group 3 - The Chongqing government-led seed fund has successfully facilitated a significant financing round for Hanpei Biotechnology, marking a breakthrough in nurturing early-stage tech projects [39][41] - The Zhejiang Provincial Innovation Investment Group is actively recruiting for various positions, emphasizing its role in managing provincial government industry funds and supporting technological innovation [9][11][19]